- Home
- FEMY vs BOLD Comparison
FEMY vs BOLD Comparison
Compare FEMY & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEMY
- BOLD
- Stock Information
- Founded
- FEMY 2004
- BOLD 2018
- Country
- FEMY United States
- BOLD United States
- Employees
- FEMY N/A
- BOLD N/A
- Industry
- FEMY Medical/Dental Instruments
- BOLD
- Sector
- FEMY Health Care
- BOLD
- Exchange
- FEMY Nasdaq
- BOLD Nasdaq
- Market Cap
- FEMY 31.9M
- BOLD 24.4M
- IPO Year
- FEMY 2021
- BOLD 2024
- Fundamental
- Price
- FEMY $0.93
- BOLD $1.16
- Analyst Decision
- FEMY Strong Buy
- BOLD Buy
- Analyst Count
- FEMY 3
- BOLD 3
- Target Price
- FEMY $8.67
- BOLD $4.00
- AVG Volume (30 Days)
- FEMY 282.0K
- BOLD 286.6K
- Earning Date
- FEMY 08-07-2025
- BOLD 08-11-2025
- Dividend Yield
- FEMY N/A
- BOLD N/A
- EPS Growth
- FEMY N/A
- BOLD N/A
- EPS
- FEMY N/A
- BOLD N/A
- Revenue
- FEMY $1,699,232.00
- BOLD N/A
- Revenue This Year
- FEMY $231.84
- BOLD N/A
- Revenue Next Year
- FEMY $245.28
- BOLD N/A
- P/E Ratio
- FEMY N/A
- BOLD N/A
- Revenue Growth
- FEMY 61.97
- BOLD N/A
- 52 Week Low
- FEMY $0.69
- BOLD $1.00
- 52 Week High
- FEMY $1.80
- BOLD $4.72
- Technical
- Relative Strength Index (RSI)
- FEMY 46.82
- BOLD N/A
- Support Level
- FEMY $0.90
- BOLD N/A
- Resistance Level
- FEMY $0.99
- BOLD N/A
- Average True Range (ATR)
- FEMY 0.06
- BOLD 0.00
- MACD
- FEMY 0.00
- BOLD 0.00
- Stochastic Oscillator
- FEMY 18.18
- BOLD 0.00
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.